The frequent silencing of tumor suppressor genes by altered cytosine methylation and chromatin structural changes makes this process an attractive target for epigenetic therapy. Here we show that zebularine, a stable DNA cytosine methylation inhibitor, is preferentially incorporated into DNA and exhibits greater cell growth inhibition and gene expression in cancer cell lines compared to normal fibroblasts. In addition, zebularine preferentially depleted DNA methyltransferase 1 (DNMT1) and induced expression of cancer-related antigen genes in cancer cells relative to normal fibroblasts. Our results demonstrate that zebularine can be selective toward cancer cells and may hold clinical promise as an anticancer therapy.
Introduction
DNA (Bouchard and Momparler, 1983; Taylor et al., 1984) . Once incorporated into DNA, both compounds can form covalent complexes with DNA methyltransferases (DNMTs), leading to a Abnormal hypermethylation of the promoters of numerous cancer-related or tumor suppressor genes important in cellular prodepletion of active enzymes (Bouchard and Momparler, 1983; Santi et al., 1983 Santi et al., , 1984 Taylor et al., 1984) . Clinically, these liferation is commonly found in primary neoplasms and tumor cell lines (Baylin et al., 2001 ; Baylin and Herman, 2000; Jones agents have already shown utility for the treatment of leukemia and myelodysplastic syndromes (Lubbert, 2000) . Nevertheless, and Baylin, 2002; Jones and Laird, 1999) . Because epigenetic processes are potentially reversible, pharmacologic inhibitors of these mechanism-based inhibitors of DNMTs have some drawbacks. Both drugs are quite toxic in vitro and in vivo, and they are DNA methylation provide a conceptually attractive and rational approach to reestablish the antiproliferative and other crucial unstable in aqueous solution, making them difficult to administer both experimentally and clinically (Beisler, 1978) . cellular functions that are abnormally silenced by hypermethylation.
We recently characterized zebularine as a novel mechanismbased inhibitor of DNA methylation, exhibiting great stability in The first described specific inhibitors of DNA methylation, 5-Azacytidine (5-Aza-CR) and its deoxy analog, 5-Aza-2Ј-deoxyacidic and neutral solutions and minimal toxicity both in vitro and in vivo (Cheng et al., 2003) . As a cytidine analog containing cytidine (5-Aza-CdR), were both originally synthesized as cancer chemotherapeutic agents (Jones and Taylor, 1980 ; Sorm et a 2-(1H)-pyrimidinone ring, zebularine was initially developed as a cytidine deaminase inhibitor, because it lacks the amino al., 1964). Both are pyrimidine ring analogs of cytidine and 2Ј-deoxycytidine, respectively, but have nitrogen atoms in place group on C-4 of the pyrimidine ring (Kim et al., 1986; Laliberte et al., 1992) . Similar to 5-Aza-CR and 5-Aza-CdR, zebularine of the C-5 pyrimidine carbon atoms. 5-Aza-CR is primarily activated by uridine-cytidine kinase and can be incorporated into has been shown to form a tight, covalent complex with bacterial methyltransferases in vitro (Hurd et al., 1999; Zhou et al., 2002) . both RNA and DNA, whereas 5-Aza-CdR is activated by deoxycytidine kinase and is only incorporated into newly synthesized However, a major concern with the usage of nucleoside analogs as inhibitors of DNA methylation is the potential for nonspecific effects toward normal cells. Zebularine can be administered to T24 cells in a continuous fashion to effectively sustain demethylation of the p16 5Ј region and other methylated loci (Cheng et al., 2004) . The purpose of this study was to compare the effects of continuous zebularine treatment on normal fibroblasts and cancer cells. We studied the incorporation of zebularine into DNA and its effects on the growth, methylation, and DNMT protein levels in a panel of four normal fibroblasts and seven cancer cell lines. Lastly, we performed a gene expression microarray chip on four normal fibroblasts and three cancer cells. We found that a larger number of genes were activated in the cancer cells than in the normal fibroblasts, and most of these genes that were activated belonged to a cluster of tumor antigen genes, including MAGE-, GAGE-, and XAGE-type cancer-testis antigens. The augmentation of tumor antigen genes by zebularine suggests that this drug may have antitumor potential in combination with immunotherapy.
Results
Zebularine preferentially inhibits the growth of cancer cells A major concern for the clinical application of nucleoside analogs is their nonspecific effects toward both normal and cancer cells. Previously, we have demonstrated the growth suppression of T24 bladder cancer cells after continuous treatment with zebularine (Cheng et al., 2004) . To further investigate the growth inhibitory effects of continuous zebularine treatment, we extended our study to a panel of seven human cancer cell lines including T24, HCT15, CFPAC-1, SW48, HT-29, PC3, and CALU-1, as well as including four normal human fibroblast cell lines (LD98, T-1, LD419, and CCD-1070Sk). Interestingly, continuous treatment with zebularine substantially retarded the growth of all human cancer cell lines, but the growth of normal Figure 1 . Effects of zebularine on growth suppression and methylation in normal and cancer cells human fibroblasts was less affected ( Figure 1A ). We next exam-A panel of normal fibroblasts (LD98, T-1, LD419, and CCD-1070Sk) and canined whether this growth inhibitory effect was associated with cer cell lines (T24 bladder cancer, HCT15, SW48, and HT-29 colon cancer, upregulation of the mRNA for p21(WAF1) and/or p27(KIP1), CFPAC-1 pancreatic cancer, PC3 prostate cancer, and CALU-1 lung canwhich are inhibitors of cyclin-CDK complexes involved in G 1 cer cells) were either untreated or treated in the presence of 10 Ϫ4 M zebularand S phase progression (Gong et al., 2003; Gotz et al., 1996;  ine continuously for 8 days. Tam et al., 1994) . Growth inhibition in cancer cells by zebularine A: The effects of zebularine on cell growth were analyzed in these cell lines by comparing doubling times before and after drug treatment. The percent was found to be associated with a 2-to 7-fold induction of the increase represents the increase in doubling time of cells after treatment p21 mRNA levels, whereas p27 mRNA levels remained relatively as compared to the untreated control cells. Expression levels of p21 and unchanged ( Figure 1A ). Both p21 and p27 mRNA were unafp27 mRNAs were determined by RT-PCR analysis. GAPDH mRNA expression fected by zebularine in all four normal fibroblasts. All of the levels were measured to control for relative cDNA input. B: The effects of zebularine on p16 gene expression and methylation of cancer cells were therefore more responsive than normal fibrovarious loci. The expression level of p16 mRNA was determined by RT-PCR blasts to the growth-suppressive effects of zebularine, and analysis. The GAPDH mRNA expression levels were the same ones shown these effects were seemingly p21-dependent. 
and demethylation
To further evaluate the enhanced growth inhibition of cancer cells by zebularine, we next analyzed the reexpression of the p16 gene, which is known to be abnormally silenced by DNA methylation levels of the 5Ј region of the p16 gene were demethylation in all of these cancer cell lines. The p16 gene was creased by zebularine treatment in the five cell lines that were expressed and was mostly unmethylated in the normal fibroinducible ( Figure 1B) . Interestingly, the p16 gene was eventually blasts, and the mRNA expression was largely unaffected by activated in CALU-1 cells after 22 days of continuous treatment zebularine treatment ( Figure 1B ). On the other hand, the p16 (data not shown), suggesting that these cells are more resistant gene was induced in T24, HCT15, CFPAC-1, SW48, and HT-29, but not in PC3 or CALU-1 cancer cells ( Figure 1B) . The to the demethylating effects of zebularine. These results also suggest that the growth inhibitory effects of zebularine may be partially due to the upregulation of p21 gene in all seven cancer cell lines and/or the induction of p16 in T24, HCT15, CFPAC-1, SW48, and HT-29 cells. We then assayed the methylation levels of two other loci that are known to be methylated in both normal and cancer cell lines. M4-4 is a single copy sequence located in a CpG island that was previously characterized in our laboratory (Cheng et al., 2004) , while D4Z4 is a subtelomeric repeat sequence (Kondo et al., 2000) . Both M4-4 and D4Z4 are highly methylated in all cell lines, and our results show that measurable demethylation was observed only in T24, HCT15, CFPAC-1, SW48, and, to a lesser extent, HT-29 cells, and minimal changes were observed in the methylation status in all normal fibroblasts, PC3, and CALU-1 cancer cells ( Figure 1B) . Consistent with the finding for the methylation of the p16 5Ј region, the methylation level of these loci was mostly unaffected by zebularine in all normal Western blot analysis of DNMT1, -3a, and -3b2/3 protein levels after continuous zebularine treatment (10 Ϫ4 M) for 8 days in a panel of (A) normal fibroDepletion of DNMT levels by zebularine blasts (LD98, T-1, LD419, and CCD-1070Sk) and (B) cancer cell lines (T24 The mechanism by which zebularine induces demethylation albladder cancer, HCT15, SW48, and HT-29 colon cancer, CFPAC-1 pancreatic cancer, PC3 prostate cancer, and CALU-1 lung cancer cells). Either most certainly requires the incorporation of the drug into the Zhou et al., 2002) . Different assays have been developed to track the levels of extractable DNMTs and individual DNMTs bound to genomic DNA using antibodies specific for each DNMT (Liu et al., 2003; Velicescu et al., 2002) . We cytidine kinase activity, since this "salvage" enzyme is responsihad previously shown the effects of continuous treatment with ble for phosphorylating zebularine to the monophosphate level, zebularine on the protein levels of DNMTs in T24 bladder cancer which is the first step for eventual incorporation into nucleic cells using Western blot analysis (Cheng et al., 2004) . It was of acids. The uridine/cytidine kinase activity levels in the cancer obvious interest to analyze the protein levels of DNMT1, -3a, cell lines were generally (3-to 40-fold) higher than that in the and -3b in the normal and cancer cells before and after continunormal fibroblasts ( Figure 3 ). The only exception was the ous zebularine treatment. Zebularine treatment decreased the CALU-1 cell line, which had low uridine/cytidine kinase activity. levels of extractable DNMT1 in all normal fibroblasts, as well We next directly measured the level of radioactive zebularine as PC3 and CALU-1 cancer cells; however, the presence of incorporated into the DNA in each cell line. Preliminary experiresidual bands on the blots suggested that methylation capacity ments (data not shown) confirmed that incorporation was dewas not completely lost (Figures 2A and 2B) . On the contrary, pendent on cell division and showed that incorporation of zebularine caused almost complete depletion of DNMT1 in T24, 2-[ 14 C]-zebularine was almost completely inhibited by the pres-HCT-15, CFPAC-1, SW48, and HT-29 cancer cells ( Figure 2B ).
ence of a 1% level of nonradioactive cytidine, confirming that The levels of DNMT3a and -3b2/3 proteins in all cell lines were the initial activation of the drug is probably dependent on uridine/ less consistently affected. The mRNA levels of each DNMT, as cytidine kinase. Our results showed a similar trend to the uridine/ measured by semiquantitative RT-PCR, remained unchanged cytidine kinase activity levels, in that cancer cells showed higher after zebularine treatment (data not shown), suggesting that the levels (2-to 50-fold) of incorporation than the normal fibroblasts. depletion of DNMT proteins was due to trapping of the enzymes These results were generally consistent with the fact that zebuto the zebularine-incorporated DNA rather than an inhibition of larine had greater inhibitory effects and demethylating effects transcription or cell proliferation. Cells that were refractory to the demethylating effects of zebularine showed partial depletion on cancer cell lines than normal fibroblasts, except for PC3 and CALU-1 cells, which both have moderate levels of DNA of DNMT1, -3a, and -3b. For instance, PC3 and CALU-1, as well as the normal fibroblasts, showed only partial depletion of incorporation, yet minimal effect on DNA methylation. These latter results suggest that incorporation of the fraudulent base DNMT1. These data suggest that a complete depletion of DNMT1 is likely a critical requirement for demethylation and into DNA is not sufficient to inhibit DNA methylation in itself and that there may be other factors that dictate the final outcome. gene induction to occur.
Cancer cells preferentially incorporate zebularine
Zebularine substantially alters gene expression in human cancer cells into DNA The differential effects of the drug on cancer cells might be due
We also wanted to investigate the effects of continuous zebularine treatment on global gene expression profiles in normal and to preferential incorporation of zebularine into DNA. In our first approach to this issue, we measured the levels of the uridine/ cancer cells. A high-density oligonucleotide gene expression
Discussion
An important concern for the clinical application of DNA methylation inhibitors is whether they will nonselectively affect normal as well as cancer cells. Here we have shown that zebularine can preferentially target cancer cells compared to normal fibroblasts, in terms of incorporation into DNA, growth inhibition, demethylation, and depletion of DNMTs. We are currently testing the generality of these findings by testing the response of normal epithelially derived cells to zebularine. While it is possible that they will not react in the same way as fibroblasts, our earlier studies using mice given daily doses of zebularine showed little evidence of toxicity (Cheng et al., 2003) . Zebularine may therefore be selective toward cancer cells and have potential as an anticancer therapy. tors are known to be differentially regulated (Gong et al., 2003;  four hours after the treatment, the cultures were harvested, and the radio- by binding to proliferating cell nuclear antigen (PCNA) (Waga et al., 1994) . The increased p21 expression points to a novel mechanism for zebularine in addition to its effects on DNA methmicroarray analysis on four normal fibroblasts (LD98, LD419, ylation. Nevertheless, other mechanisms, such as the induction T-1, and CCD-1070k) and three cancer cell lines (T24, CFPAC-1, of apoptosis, may play an important role in the growth regulation and HCT15) showed that a common set of 12 genes were of the cancer cells treated by zebularine (Nieto et al., 2004) . upregulated by Ն2-fold after 8 days of continuous drug treat-
The preferential effects of zebularine for cancer cells are ment in all three cancer cell lines, but not in the normal fibroprobably due to differential metabolism compared to normal blasts (Table 1A) . Interestingly, eight of these (67%) belonged cells. The drug requires activation by phosphorylation before it to a cluster of tumor antigens, which include MAGE-, GAGE-, can be incorporated into nucleic acids, and the conversion of and XAGE-cancer-testis antigens (Table 1A) . The level of inthe nucleoside to the monophosphate is the first step in this duced expression varied from 2-fold for MAGEA1 to a maximum process, which is catalyzed by the uridine/cytidine kinase enof 315-fold for SPANXA1 in T24 cells. The microarrays did not zyme. Once phosphorylated, the 2-(1H)-pyrimidinone ring can detect the upregulation of p16 or p21 that was found earlier be incorporated into RNA and into DNA after the reduction by (Figure 1) , possibly due to technical issues related to the fact ribonucleotide reductase of the ribose moiety to deoxyribose. that multiple transcripts are present in the p16 gene, making it Our data support the idea that uridine/cytidine kinase may serve difficult for the software to score the low signal intensities. We as a potential gateway enzyme that predetermines the amount cannot, however, explain the discrepancy between the results of zebularine that eventually gets into the DNA and probably obtained for p21 expression. However, we previously verified RNA. Since lower levels of this enzyme were present in the that genes detected as being increased on microarrays were normal cells, we would indeed expect less zebularine incorporaalso shown to be upregulated by RT-PCR (Liang et al., 2002) . tion into both RNA and DNA of normal fibroblasts. This was A total of 6 out of 13,300 genes were found to be downregustrongly supported by the incorporation data. Nevertheless, the lated in all three cancer cell lines by continuous zebularine treatlevel of uridine/cytidine kinase activity does not correlate perment (Table 1B) . Similarly, only one gene out of 13,000 genes fectly with the level of radioactive zebularine incorporation into examined was found to be upregulated or downregulated in the DNA, probably due to fact that other enzymes in this pathway might alter the incorporation into the DNA. common in all four normal fibroblasts (Tables 1C and 1D ). This result supports the idea that zebularine is relatively nontoxic in
The incorporation of the 2-(1H)-pyrimidinone ring into DNA is almost certainly required for the depletion of DNMT1 and the that only a small number of genes were globally affected by zebularine. Our earlier work on the global effects of gene expresinhibition of DNA methylation that we observed in five of the seven cancer cells. A disparity between the lack of demethylsion by 5-Aza-CdR in both T24 and LD419 cell lines (Liang et al., 2002) , as well as others, has also shown that a cluster of ation and zebularine incorporation was observed in both CALU-1 and PC3 cancer cells by day 8 of continuous zebularine tumor antigens was activated in cancer cells but not in normal cells (Karpf et al., 2004) . Altogether, our data suggest the potentreatment. We do not have an explanation for this observation at present; however, treatment of CALU-1 cells with continuous tial utilization of zebularine in the upregulation of these tumor antigens, which constitute promising targets for immunotherapy zebularine eventually reactivated the p16 gene by day 22, which suggests that there may be a different threshold for each cell (Gillespie and Coleman, 1999; Weber et al., 1994). line in terms of the amount of zebularine incorporation required of polyribosomes, coacceptor function of tRNA, and marked inhibition of protein synthesis (Li et al., 1970 ; Momparler et in order for demethylation and gene activation to occur. The threshold levels might be quite variable between each cell line, al., 1976; Reichman and Penman, 1973) . The incorporation of zebularine into RNA could thereby also conceivably explain the since other factors, such as the rate of DNA repair, rate of zebularine mutation, rate of DNA synthesis, ploidy numbers, growth inhibitory properties of the drug in all cancer cell lines, including CALU-1 and PC3 cells. Zebularine might therefore be trans-acting factors, and potentially others may influence these cells. Nevertheless, the cancer cells in general showed a greater multifactorial in its effects, but the preferential activity in cancer cells makes it an exciting drug. level of incorporation of zebularine, which is consistent with the growth inhibitory and demethylating effects observed in most
The differential depletion of DNMTs by zebularine in the normal and cancer cell lines is quite interesting. The levels of of these cells.
The growth inhibitory effects of zebularine appeared to cor-DNMT1, DNMT3a, and DNMT3b2/3 were less affected in normal fibroblasts after zebularine treatment, consistent with the obserrelate well with the level of zebularine incorporation into the DNA. The normal cells had low zebularine incorporation and vation that less zebularine is incorporated into their DNA. The cancer cells that responded to zebularine in terms of demethylexhibited minimal yet measurable effects on growth inhibition, while the cancer cells had high levels of zebularine incorporation ation showed a complete depletion of DNMT1 and partial depletion of DNMT3a and DNMT3b2/3. We had previously shown and exhibited greater growth inhibition. This suggests that the growth inhibition seen in cancer cells but not in normal cells that zebularine preferentially depletes DNMT1 over the other DNMTs in T24 cells (Cheng et al., 2004) , implicating a more may have resulted directly from the incorporation of the drug into the DNA and the effects thereafter. Nonetheless, one cannot specific and higher affinity of this drug for DNMT1. We have also previously shown that both 5-Aza-CdR and zebularine display rule out the possibility that the growth-inhibitory effects may also be exerted through their incorporation into RNA, which is differential depletion of DNMTs in T24 cells using Western blot analysis (Cheng et al., 2004; Velicescu et al., 2002) . The comlikely, since preliminary experiments have shown that the 2-(1H)-pyrimidinone ring can be found in the RNA of treated T24 cells plete depletion of DNMT1 appeared to correlate with the demethylation of various loci in these cell lines, suggesting that at levels ten times greater than the incorporation into the DNA (T. Ben-Kasus et al., 2004, Proc. AACR, abstract) . The incorpo-DNMT1 depletion may be an important indicator of the demethylating ability of zebularine. ration of 5-Aza-CR into RNA is known to produce disassembly SW48, HT-29, LD419, LD98, and T-1 cells were cultured in McCoy's 5A
The reason for the apparent specificity of the 2-(1H)-pyrimimedium supplemented with 10% heat-inactivated fetal calf serum (FCS), dinone ring for the DNMT1 enzyme is unexpected, since all 100 units/ml penicillin, and 100 g/ml streptomycin (Gibco/Life Technoloknown cytosine-5 DNMTs appear to utilize the same mechanism gies, Inc., Palo Alto, CA). HCT15 was cultured in RPMI 1640 medium suppleof action (Cheng and Roberts, 2001 ). Perhaps zebularine exhibmented with 10% FCS, penicillin/streptomycin, and 1ϫ sodium pyruvate its a greater enzymatic binding affinity for DNMT1 than for the (Gibco/Life Technologies, Inc.). CFPAC-1 was cultured in IMDM medium other DNMTs. However, this is still unclear and needs to be supplemented with 10% FCS, penicillin/streptomycin, and 1ϫ glutamine (Gibco/Life Technologies, Inc.). CALU-1 was cultured in McCoy's 5A medium clarified. Nevertheless, it was recently shown that DNMT3b3 supplemented with 10% FCS, penicillin/streptomycin, and 1ϫ glutamine.
isoform has a reduced catalytic activity (Okano et al., 1999;  PC3 was cultured in RPMI 1640 medium supplemented with 5% FCS and Soejima et al., 2003) , which might compromise its ability to penicillin/streptomycin. CCD-1070Sk was cultured in MEM medium supplecomplex with zebularine, thereby explaining the partial depletion mented with 10% FCS, penicillin/streptomycin, 1ϫ sodium pyruvate (Gibco/ of this enzyme by the drug. In addition, the partial depletion of Life Technologies, Inc.), and 1ϫ MEM nonessential amino acids (Gibco/Life DNMT3a by zebularine could potentially be due to the fact Technologies, Inc.) . All cultures were grown in a humidified incubator at 37ЊC in 5% CO 2 .
that DNMT3a protein is expressed throughout the cell cycle, as opposed to DNMT1 and DNMT3b, which are cell cycle regulated Drug treatments (Robertson et al., 2000) , and the depletion of DNMT3a can All normal and cancer cell lines were plated (3 ϫ 10 5 cells/100 mm dish) therefore only occur during the S phase, in which the 2-(1H)-and treated 24 hr later with 10 Ϫ4 M zebularine continuously for 8 days. The pyrimidinone ring is incorporated into the DNA.
medium was changed every 3 days thereafter along with fresh zebularine.
Our microarray data suggest that a combinatorial approach DNA, RNA, and protein lysates were harvested at the end of the treatment for the treatment of human cancers could involve the use of period for methylation, RT-PCR, and Western blot analyses, respectively.
demethylating agents to augment the presentation of specific
Nucleic acid isolation
cell surface antigens, which could then be targeted by immuno-RNA was collected and extracted from cultured cells using the RNeasy therapy. Indeed, early studies by Frost et al. (1984) showed that Protect Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's 5-Aza-CR could induce the formation of strongly immunogenic recommended protocol. DNA was collected as previously described (Gonzavariants of mouse cells, providing support for this concept (Frost lez-Zulueta et al., 1995 . The activation of cancer-related or tumor antigens of the MAGE family has been observed in a number of human
RT-PCR analysis
Total RNA (5 g) extracted from cultured cells was reverse transcribed cancers, and this was shown to correlate with genomic DNA using MMLV reverse transcriptase (Invitrogen, Carlsbad, CA) and random hypomethylation (De Smet et al., 1996) . Based on these obserhexamers (Amersham-Pharmacia, Piscataway, NJ) in a total volume of 25 vations, therapeutic strategies have been recently developed l. The reverse transcription (RT) was performed as previously described that strive to direct cellular immunity toward tumors that express (Gonzalez-Zulueta et al., 1995) . cDNA was amplified with primers specific MAGE antigens (Gillespie and Coleman, 1999) . A caveat of this for either p16, p21, p27, or glyceraldehyde-3-phosphate dehydrogenase strategy is that the majority of human tumors do not express ability to sustain demethylation through continuous administra-PCR products were resolved on 2% agarose gels.
tion, zebularine is also relatively selective toward cancer cells and thus represents a promising candidate for epigenetic
Oligonucleotide array analysis cRNA preparation therapy.
Total RNA (10 g) was used as starting material for the cDNA preparation. The first and second strand cDNA synthesis was performed using the Super-
Experimental procedures
Script II System (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions, except using an oligo-dT primer containing a T7 RNA Cell lines T24 (bladder transitional carcinoma cells), HCT15, SW48, and HT-29 (colon polymerase promoter site. Labeled cRNA was prepared using the BioArray High Yield RNA Transcript Labeling Kit (Enzo Life Sciences, Inc., Farmingcarcinoma cells), CFPAC-1 (pancreatic carcinoma cells), CALU-1 (lung carcinoma cells), and CCD-1070Sk (human normal fibroblasts) were obtained dale, NY). Biotin-labeled CTP and UTP (Enzo) were used in the reaction, together with unlabeled triphosphates. Following the in vitro transcription from the American Type Culture Collection (Rockville, MD). PC3 (prostate carcinoma) cells were kindly provided by Dr. Gerry Coetzee. LD419, LD98, reaction, the unincorporated nucleotides were removed using RNeasy columns (Qiagen). and T-1 (human normal fibroblasts) were established in our laboratory. T24,
Array hybridization and scanning
and 72ЊC for 20 s. The D4Z4 SNuPE primers are as follows: 5Ј-TGA GGG Fifteen micrograms of cRNA was fragmented at 94ЊC for 35 min in a buffer TTG GGT TTA TAG T-3Ј, 5Ј-GTG GTT TAG GGA GTG GG-3Ј, 5Ј-TAT ATT containing 40 mM Tris-acetate (pH 8.1), 100 mM potassium acetate, 30 mM TTT AGG TTT AGT TTT GTA A-3Ј, 5Ј-GAA AGG TTG GTT ATG T-3Ј. The magnesium acetate. Prior to hybridization, the fragmented cRNA in a 6ϫ
M4-4 SNuPE primers are as follows: 5Ј-GGG TTT AGA TTA GGT TTT TT-3Ј, SSPE-T hybridization buffer (1 M NaCl, 10 mM Tris [pH 7.6], 0.005% Triton) 5Ј-GTA ATA AGG ATT ATT TGA ATA G-3Ј, 5Ј-TAA TAA TGT GGA TTT GTT was heated to 95ЊC for 5 min and subsequently to 45ЊC for 5 min before TAA ATT-3Ј. loading onto the Affymetrix HG_U133A probe array cartridge. The probe array was then incubated for 16 hr at 45ЊC at constant rotation (60 rpm).
Radioactive incorporation assay The washing and staining procedure was performed in the Affymetrix Fluidics All cell lines were plated (2 ϫ 10 5 cells/60 mm dish) and treated 24 hr later Station. The probe array was exposed to ten washes in 6ϫ SSPE-T at 25ЊC, with 0.75 Ci/ml 2-[ 14 C]-zebularine for 24 hr. A separate dish of untreated followed by four washes in 0.5ϫ SSPE-T at 50ЊC. The biotinylated cRNA cells was used for each cell line to determine the total number of cells per was stained with a streptavidin-phycoerythrin conjugate (final concentration dish at the end of 24 hr treatment with a Z1 Coulter Particle Counter (Beckof 2 mg/ml; Molecular Probes, Eugene, OR) in 6ϫ SSPE-T for 30 min at 25ЊC, man Coulter Corporation, Hialeah, FL). Cells were washed three times with followed by ten washes in 6ϫ SSPE-T at 25ЊC. An antibody amplification step PBS, trypsinized, suspended in 450 l of water, lysed with 0.3 M KOH, and was followed using normal goat IgG as blocking reagent (final concentration then incubated at 37ЊC for 18 hr to hydrolyze RNA. Protein and DNA were of 0.1 mg/ml; Sigma) and biotinylated anti-streptavidin goat antibody (final precipitated with 90% trichloroacetic acid (TCA) on ice for 5 min, and the concentration of 3 mg/ml; Vector Laboratories, Burlingame, CA). This was DNA pellet was thoroughly washed with 5% TCA and hydrolyzed in 100 l followed by a staining step with a streptavidin-phycoerythrin conjugate (final of 5% TCA for 30 min. The samples were centrifuged, and radioactivity in concentration of 2 mg/ml; Molecular Probes) in 6ϫ SSPE-T for 30 min at 50 l of supernatant was counted in 10 ml of scintillation fluid (Research 25ЊC and 10 washes in 6ϫ SSPE-T at 25ЊC. The probe arrays were scanned Products International Corp., Mt. Prospect, IL) in a Packard Tri-Carb 1600 at 560 nm using a confocal laser-scanning microscope (Hewlett Packard TR Liquid Scintillation Spectrometer (Downers Grove, IL). GeneArray Scanner G2500A; Affymetrix, Inc., Santa Clara, CA). The readings from the quantitative scanning were analyzed by the Affymetrix Gene ExpresUridine/cytidine kinase activity sion Analysis Software. In our analysis, genes that were induced or
The uridine/cytidine kinase activity in normal fibroblasts and cancer cells reduced Ն3-fold after drug treatment were categorized into different groups.
was measured using assays modified as described by Luccioni et al. (1994) .
Western blot analysis of DNMT protein levels Determination of cell doubling times Cells were lysed by the addition of radioimmunoprecipitation (RIPA) buffer All cultured cells (3 ϫ 10 5 cells/100 mm dish) were plated and treated with (PBS, 0.1% SDS, 0.5% nonidet P-40, and 0.5% sodium deoxycholate), and 10 Ϫ4 M zebularine 24 hr later and continuously for 8 days, with fresh zebularprotein extracts were prepared as previously described (Velicescu et al., ine and media changes every 3 days. The cell number/dish was counted 2002). Approximately 60 g total protein extract was electrophoresed and with a Z1 Coulter Particle Counter (Beckman Coulter Corporation, Hialeah, transferred to PVDF membranes overnight at 4ЊC as previously described FL) every 2 to 3 days. Untreated cells were analyzed under similar conditions (Velicescu et al., 2002) . The membranes were hybridized with antibodies as a control. The average cell number from two plates was determined, and against human DNMT1 (1:1000 dilution; New England Biolabs, Beverly, MA), the mean cell numbers were plotted to define the cell population doubling human DNMT3b (T-16; 1:500 dilution; Santa Cruz Biotechnology, Santa times. Initial drug treatment was started 24 hr after seeding. Cruz, CA), and proliferating cell nuclear antigen (PCNA) (1:4000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) in Tris-buffered saline-Tween
